First Trust Advisors
LYEL icon

First Trust Advisors’s Lyell Immunopharma LYEL Stock Holding History

First Trust Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,369
Closed -$1.07M – 2427
2022
Q4 		$1.07M Buy
15,369
+1,525
+11% +$151K ﹤0.01% 1942
2022
Q3 		$2.03M Buy
+13,844
New +$1.87M ﹤0.01% 1668

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

First Trust Advisors's LYEL Position: Q1 2023 in Review

First Trust Advisors sold out of Lyell Immunopharma (LYEL) in Q1 2023, closing a stake of 15,369 shares — an estimated $1.07M sold.

First Trust Advisors first reported a position in LYEL in Q3 2022 and held it in 2 quarters. The position peaked at $2.03M in Q3 2022. 99 funds tracked by Wall St. Rank hold LYEL as of Q1 2023.

  • First Trust Advisors reported no remaining Lyell Immunopharma position as of Q1 2023 after selling out during the quarter.
  • First Trust Advisors sold 15,369 Lyell Immunopharma shares in Q1 2023, an estimated $1.07M.
  • First Trust Advisors first reported a position in Lyell Immunopharma in Q3 2022 and held it in 2 quarters.
  • First Trust Advisors's Lyell Immunopharma position peaked at $2.03M in Q3 2022.
  • 99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2023.

Based on First Trust Advisors's 13F filing for Q1 2023, filed 15 May 2023.